US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals’ Ocaliva in patients with primary biliary cholangitis.
Read More
The Scottish Medicines Consortium has accepted four new medicines for routine use by NHS Scotland, offering patients new options for kidney cancer, liver disease and the prevention of nausea and vomiting.
Read More
Intercept’s Ocaliva is being backed by the National Institute for Health and Care Excellence for routine NHS commissioning as a treatment for people with the chronic liver disease primary biliary cholangitis (PBC).
Read More
The European Commission has cleared Intercept’s Ocaliva for the treatment of primary biliary cholangitis (PBC), giving patients the potential to access the first new therapy for the condition in nearly 20 years.
Read More
Eight medicines have taken a big leap towards being approved in Europe having won the support of the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
